What insurance policy changes affect CPT 93463?

There are 8 tracked policy changes affecting CPT 93463, including updates from Humana. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for CPT 93463?

Payers that have issued tracked updates for CPT 93463 include: Humana.

How do I get notified when CPT 93463 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to CPT 93463. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for CPT 93463?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

93463 — Administering medication through a catheter while simultaneously measuring the heart's pumping pressures and blood flow.: Insurance Policy Changes

93463 Insurance Policy Changes

CPT 93463, in plain terms, covers Administering medication through a catheter while simultaneously measuring the heart's pumping pressures and blood flow. CPT 93463 is referenced in 8 tracked payer policy changes from Humana. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 93463 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Medium impact

Inhaled Nitric Oxide - MEDICAID - MICHIGAN (New)

Humana·Effective Jan 1, 2026

Humana Medicaid Michigan has established a new policy for inhaled nitric oxide (iNO) coverage effective January 1, 2026. The policy covers iNO for specific conditions including postoperative pulmonary hypertension management in pediatric congenital heart disease, vasoreactivity testing in adults with pulmonary arterial hypertension, and hypoxic respiratory failure in term/near-term infants with persistent pulmonary hypertension of the newborn, with strict criteria and a 14-day maximum treatment duration.

93463 Insurance Policy Changes

Inhaled Nitric Oxide - MEDICAID - LOUISIANA (Revised)

Inhaled Nitric Oxide - MEDICAID - INDIANA (New)

Inhaled Nitric Oxide - MEDICAID - FLORIDA (Revised)

Inhaled Nitric Oxide - MEDICAID - VIRGINIA (Revised)

Inhaled Nitric Oxide - MEDICAID - MICHIGAN (New)

Inhaled Nitric Oxide - MEDICAID - SOUTH CAROLINA (Revised)

Inhaled Nitric Oxide - MEDICAID - OKLAHOMA (Revised)

Inhaled Nitric Oxide - MEDICAID - KENTUCKY (Revised)